JOHN KIRKWOOD to Drug Evaluation, Preclinical
This is a "connection" page, showing publications JOHN KIRKWOOD has written about Drug Evaluation, Preclinical.
Connection Strength
0.107
-
Tremelimumab, a fully human monoclonal IgG2 antibody against CTLA4 for the potential treatment of cancer. Curr Opin Mol Ther. 2007 Oct; 9(5):505-14.
Score: 0.071
-
The levels of mutant K-RAS and mutant N-RAS are rapidly reduced in a Beclin1 / ATG5 -dependent fashion by the irreversible ERBB1/2/4 inhibitor neratinib. Cancer Biol Ther. 2018 02 01; 19(2):132-137.
Score: 0.036